OP Asset Management’s Biogen BIIB Stock Holding History

OP Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.62M	Buy	16,758 +1,495	+10%	+$286K	0.04%	324
2026 Q1	$2.8M	Sell	15,263 -983	-6%	-$181K	0.02%	375
2025 Q4	$2.86M	Hold	16,246	–	–	0.03%	342
2025 Q3	$2.28M	Hold	16,246	–	–	0.03%	399
2025 Q2	$2.04M	Buy	16,246 +811	+5%	+$101K	0.03%	420
2025 Q1	$2.11M	Buy	+15,435	New	+$2.21M	0.04%	393

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OP Asset Management's BIIB Position: Q2 2026 in Review

OP Asset Management increased its Biogen (BIIB) stake by 9.8% in Q2 2026, buying an estimated $286K and bringing the position to 16,758 shares worth $3.62M. The position accounts for 0.04% of the portfolio, ranked #324.

OP Asset Management first reported a position in BIIB in Q1 2025 and has held it in 6 quarters since. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

OP Asset Management held 16,758 shares of Biogen worth $3.62M as of Q2 2026.
OP Asset Management bought 1,495 Biogen shares in Q2 2026, an estimated $286K.
Biogen made up 0.04% of OP Asset Management's portfolio in Q2 2026, its #324 holding.
OP Asset Management first reported a position in Biogen in Q1 2025 and has held it in 6 quarters since.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.